Joon Lee
Stock Analyst at Truist Securities
(4.37)
# 454
Out of 4,412 analysts
77
Total ratings
43.66%
Success rate
30.29%
Average return
Main Sectors:
Top Industries:
21 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Maintains: Hold | $22 → $18 | $13.69 | +31.48% | 5 | Apr 26, 2024 | |
| MRNS Marinus Pharmaceuticals | Maintains: Buy | $25 → $10 | $1.41 | +611.74% | 6 | Apr 17, 2024 | |
| WVE Wave Life Sciences | Reiterates: Buy | $17 | $4.66 | +264.81% | 2 | Apr 1, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $150 | $71.71 | +109.18% | 2 | Mar 26, 2024 | |
| ARVN Arvinas | Reiterates: Buy | $65 | $32.37 | +100.80% | 5 | Mar 25, 2024 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Buy | $200 | $109.46 | +82.72% | 2 | Mar 20, 2024 | |
| ARGX argenx SE | Maintains: Buy | $370 → $440 | $372.80 | +18.03% | 8 | Mar 5, 2024 | |
| VKTX Viking Therapeutics | Maintains: Buy | $32 → $120 | $74.31 | +61.49% | 5 | Feb 29, 2024 | |
| CORT Corcept Therapeutics | Maintains: Buy | $36 → $42 | $22.80 | +84.21% | 3 | Feb 16, 2024 | |
| CRMD CorMedix | Maintains: Buy | $18 → $14 | $5.31 | +163.65% | 4 | Jan 31, 2024 | |
| EDIT Editas Medicine | Maintains: Buy | $15 → $20 | $5.32 | +275.94% | 5 | Dec 12, 2023 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $220 → $160 | $53.91 | +196.79% | 3 | Dec 11, 2023 | |
| PRAX Praxis Precision Medicines | Reiterates: Buy | $150 | $54.80 | +173.72% | 2 | Dec 4, 2023 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $6 → $5 | $2.39 | +109.21% | 7 | Sep 20, 2023 | |
| ADVM Adverum Biotechnologies | Reiterates: Buy | $60 | $9.19 | +552.88% | 4 | Sep 5, 2023 | |
| VRNA Verona Pharma | Reiterates: Buy | $32 | $15.47 | +106.85% | 3 | Jun 27, 2023 | |
| CPRX Catalyst Pharmaceuticals | Maintains: Buy | $22 → $24 | $14.89 | +61.18% | 5 | Jun 21, 2023 | |
| VYGR Voyager Therapeutics | Initiates: Buy | $18 | $7.62 | +136.22% | 1 | May 10, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Buy | n/a | $20.76 | - | 2 | Jun 28, 2021 | |
| TBIO Telesis Bio | Downgrades: Hold | n/a | $0.32 | - | 2 | Mar 18, 2021 | |
| ANAB AnaptysBio | Upgrades: Buy | n/a | $21.00 | - | 1 | Mar 16, 2021 |
Sage Therapeutics
Apr 26, 2024
Maintains: Hold
Price Target: $22 → $18
Current: $13.69
Upside: +31.48%
Marinus Pharmaceuticals
Apr 17, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $1.41
Upside: +611.74%
Wave Life Sciences
Apr 1, 2024
Reiterates: Buy
Price Target: $17
Current: $4.66
Upside: +264.81%
Axsome Therapeutics
Mar 26, 2024
Maintains: Buy
Price Target: $150
Current: $71.71
Upside: +109.18%
Arvinas
Mar 25, 2024
Reiterates: Buy
Price Target: $65
Current: $32.37
Upside: +100.80%
Jazz Pharmaceuticals
Mar 20, 2024
Reiterates: Buy
Price Target: $200
Current: $109.46
Upside: +82.72%
argenx SE
Mar 5, 2024
Maintains: Buy
Price Target: $370 → $440
Current: $372.80
Upside: +18.03%
Viking Therapeutics
Feb 29, 2024
Maintains: Buy
Price Target: $32 → $120
Current: $74.31
Upside: +61.49%
Corcept Therapeutics
Feb 16, 2024
Maintains: Buy
Price Target: $36 → $42
Current: $22.80
Upside: +84.21%
CorMedix
Jan 31, 2024
Maintains: Buy
Price Target: $18 → $14
Current: $5.31
Upside: +163.65%
Editas Medicine
Dec 12, 2023
Maintains: Buy
Price Target: $15 → $20
Current: $5.32
Upside: +275.94%
CRISPR Therapeutics AG
Dec 11, 2023
Maintains: Buy
Price Target: $220 → $160
Current: $53.91
Upside: +196.79%
Praxis Precision Medicines
Dec 4, 2023
Reiterates: Buy
Price Target: $150
Current: $54.80
Upside: +173.72%
Taysha Gene Therapies
Sep 20, 2023
Maintains: Buy
Price Target: $6 → $5
Current: $2.39
Upside: +109.21%
Adverum Biotechnologies
Sep 5, 2023
Reiterates: Buy
Price Target: $60
Current: $9.19
Upside: +552.88%
Verona Pharma
Jun 27, 2023
Reiterates: Buy
Price Target: $32
Current: $15.47
Upside: +106.85%
Catalyst Pharmaceuticals
Jun 21, 2023
Maintains: Buy
Price Target: $22 → $24
Current: $14.89
Upside: +61.18%
Voyager Therapeutics
May 10, 2023
Initiates: Buy
Price Target: $18
Current: $7.62
Upside: +136.22%
Intellia Therapeutics
Jun 28, 2021
Maintains: Buy
Price Target: n/a
Current: $20.76
Upside: -
Telesis Bio
Mar 18, 2021
Downgrades: Hold
Price Target: n/a
Current: $0.32
Upside: -
AnaptysBio
Mar 16, 2021
Upgrades: Buy
Price Target: n/a
Current: $21.00
Upside: -